1204 related articles for article (PubMed ID: 22827747)
1. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
Bergsdorf C; Ottl J
Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
[TBL] [Abstract][Full Text] [Related]
2. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
3. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
Bergsdorf C; Wright SK
Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
[TBL] [Abstract][Full Text] [Related]
4. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
Hennig M; Ruf A; Huber W
Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
[TBL] [Abstract][Full Text] [Related]
5. Applications of Biophysics in High-Throughput Screening Hit Validation.
Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
[TBL] [Abstract][Full Text] [Related]
6. Hit finding: towards 'smarter' approaches.
Langer T; Hoffmann R; Bryant S; Lesur B
Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
[TBL] [Abstract][Full Text] [Related]
7. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
8. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
Genick CC; Wright SK
Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
[TBL] [Abstract][Full Text] [Related]
9. Increasing the delivery of next generation therapeutics from high throughput screening libraries.
Wigglesworth MJ; Murray DC; Blackett CJ; Kossenjans M; Nissink JW
Curr Opin Chem Biol; 2015 Jun; 26():104-10. PubMed ID: 25909818
[TBL] [Abstract][Full Text] [Related]
10. Which aspects of HTS are empirically correlated with downstream success?
Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.
Heeres JT; Hergenrother PJ
Chem Soc Rev; 2011 Aug; 40(8):4398-410. PubMed ID: 21140010
[TBL] [Abstract][Full Text] [Related]
12. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
13. Non-stoichiometric inhibition in integrated lead finding - a literature review.
Klumpp M
Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
[TBL] [Abstract][Full Text] [Related]
14. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
15. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
Danielson UH
Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based lead discovery on G-protein-coupled receptors.
Visegrády A; Keserű GM
Expert Opin Drug Discov; 2013 Jul; 8(7):811-20. PubMed ID: 23621346
[TBL] [Abstract][Full Text] [Related]
17. Biophysical methods in drug discovery from small molecule to pharmaceutical.
Holdgate G; Geschwindner S; Breeze A; Davies G; Colclough N; Temesi D; Ward L
Methods Mol Biol; 2013; 1008():327-55. PubMed ID: 23729258
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in fragment-based lead discovery.
Schulz MN; Hubbard RE
Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
[TBL] [Abstract][Full Text] [Related]
19. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
Duffy BC; Zhu L; Decornez H; Kitchen DB
Bioorg Med Chem; 2012 Sep; 20(18):5324-42. PubMed ID: 22938785
[TBL] [Abstract][Full Text] [Related]
20. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
